David M Gershenson
Overview
Explore the profile of David M Gershenson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
251
Citations
9244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gershenson D, Ledermann J, Ray-Coquard I
Int J Gynecol Cancer
. 2025 Feb;
35(3):101677.
PMID: 39983367
No abstract available.
2.
Brodsky A, Flores Legarreta A, How J, Vuttaradhi V, Sood A, Ramondetta L, et al.
Am J Obstet Gynecol
. 2025 Jan;
PMID: 39824329
Background: Adult-type granulosa cell tumors are a rare form of ovarian cancer, 30% of which will recur. Cytoreductive surgery is often performed at the time of a first recurrence, but...
3.
Welte T, Vuttaradhi V, Khlebus E, Brodsky A, Flores Legarreta A, Celestino J, et al.
Cancer Res
. 2024 Dec;
85(5):875-893.
PMID: 39652611
Adult type ovarian granulosa cell tumors (AGCT) are rare malignancies with the near universal c.C402G (p.Cys134Trp) somatic mutation in FOXL2, a forkhead box family transcription factor important for ovarian function....
4.
Liu J, Berchuck A, Backes F, Cohen J, Grisham R, Leath C, et al.
J Natl Compr Canc Netw
. 2024 Oct;
22(8):512-519.
PMID: 39413835
The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of...
5.
Rushton T, Krause H, Samec T, Elliott A, Karnezis A, Toboni M, et al.
Gynecol Oncol
. 2024 Oct;
191:80-85.
PMID: 39366033
Objective: Targeted therapy in folate receptor alpha (FOLR1)-positive high grade serous ovarian carcinoma (HGSOC) is now a mainstay for platinum-resistant disease. However, the rate of FOLR1-positivity in low grade serous...
6.
Brown J, Miller A, Holman L, Backes F, Nagel C, Bender D, et al.
Gynecol Oncol
. 2024 Sep;
190:283-290.
PMID: 39265466
Objectives: To assess the efficacy and toxicity of paclitaxel and carboplatin (PC) compared to bleomycin, etoposide, and cisplatin (BEP) for treatment of newly diagnosed Stage IIA-IV or recurrent chemotherapy-naive ovarian...
7.
Matsuo K, Chen L, Klar M, Roman L, Sood A, Gershenson D, et al.
JAMA Netw Open
. 2024 Jun;
7(6):e2417775.
PMID: 38900429
No abstract available.
8.
Son J, Zhang Y, Lin H, Mirallas O, Alvarez Ballesteros P, Nardo M, et al.
Clin Cancer Res
. 2024 Apr;
30(14):2986-2995.
PMID: 38687597
Purpose: We aimed to describe RAS mutations in gynecologic cancers as they relate to clinicopathologic and genomic features, survival, and therapeutic implications. Experimental Design: Gynecologic cancers with available somatic molecular...
9.
Gien L, Enserro D, Block M, Waggoner S, Duska L, Wahner-Hendrickson A, et al.
Gynecol Oncol
. 2024 Apr;
186:61-68.
PMID: 38603953
Introduction: Early reports of PD-1 inhibition in ovarian clear cell carcinomas (OCCC) demonstrate promising response. We evaluated the combination of pembrolizumab and IDO-1 inhibitor epacadostat in patients with recurrent OCCC....
10.
Ng C, Tsang Y, Gershenson D, Wong K
Br J Cancer
. 2024 Apr;
130(11):1875-1884.
PMID: 38582811
Background: Other than for breast cancer, endocrine therapy has not been highly effective for gynecologic cancers. Endocrine therapy resistance in estrogen receptor positive gynecologic cancers is still poorly understood. In...